Targeting aldehyde dehydrogenase in hepatocellular carcinoma:mechanistic insights and therapeutic advances
10.7659/j.issn.1005-6947.240681
- VernacularTitle:靶向醛脱氢酶在肝细胞癌发生机制与治疗策略中的研究进展
- Author:
Xuelong DU
1
;
Xiaojun YANG
Author Information
1. 甘肃中医药大学第一临床医学院,甘肃 兰州 730000;甘肃省人民医院 普通外科,甘肃 兰州 730000;甘肃省外科肿瘤分子诊断与精准治疗重点实验室、甘肃省消化道恶性肿瘤防控工程研究中心、国家卫生健康委胃肠肿瘤诊治重点实验室,甘肃 兰州 730000
- Publication Type:Journal Article
- Keywords:
Carcinoma,Hepatocellular;
Aldehyde Dehydrogenase;
Neoplastic Stem Cells;
Immunotherapy;
Reviewe
- From:
Chinese Journal of General Surgery
2025;34(7):1532-1541
- CountryChina
- Language:Chinese
-
Abstract:
Hepatocellular carcinoma(HCC)is a highly heterogeneous malignancy with poor prognosis,closely linked to oxidative stress,metabolic reprogramming,and tumor microenvironment alterations.Aldehyde dehydrogenase(ALDH)plays multifaceted roles in HCC by regulating oxidative stress,modulating glucose and lipid metabolism,sustaining cancer stem cell properties,and promoting immune evasion,making it a promising therapeutic target.This review summarizes the expression patterns and mechanistic functions of ALDH in HCC,highlights advances in ALDH-targeted therapies,including inhibitors such as disulfiram and diethylaminobenzaldehyde,and ALDH-based peptide vaccines-and discusses their potential in combination with immunotherapy and chemotherapy.Current evidence suggests that ALDH inhibition can suppress tumor growth,reverse drug resistance,and enhance antitumor immunity.Future research should aim to improve drug selectivity and safety,and to develop personalized combination strategies to optimize clinical outcomes in HCC patients.
